Not So Different: A Podcast from The Center for Biosimilars
"Not So Different," a podcast from The Center for Biosimilars, brings you expert viewpoints from physicians, pharmacists, patients, developers, and other stakeholders in the complex world of biosimilar therapies.
Episodes
References
Jeremias S. The Biosimilar Void: 9...
Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars
To learn more about the 10th anniversary of the first FDA biosimilar approval, click here.
To learn more about how much biosimilars have saved so far, click here.
To read more about Josh's views on the pharmaceutical landscape in 2025, click here.
To learn more about the FTC's most recent report on PBMs, click here.
To learn more about the FTC's first report on PBMs, click here.
To learn more about health care actions taken by the second Trump Administration during it's first month, click here.
To learn more about the views of Mehmet Oz, MD (more commonly known as Dr. Oz) on price transparency ahead of his congressional confirmation heari...
Show notes
Number 4: Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
Number 3: Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
Number 2: Biosimilars in America: Overcoming B...
1. Jeremias S. Skyrizi overtakes Humira: “product hopping” leaves biosimilar market in limbo. The Center for Biosimilars. November 7, 2024. Accessed November 27, 2024. https://www.centerforbiosimilars.com/view/skyrizi-overtakes-humira-product-hopping-leaves-biosimilar-market-in-limbo
To check out our coverage of the recent GRx+Biosims conference Craig mentioned, click here.
To learn more about product hopping, click here.
To read part 2 of our GBW series, click here.
To read part 3 of our GBW series, click here.
To hear another episode featuring more of Craig's t...
2. AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
3. Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
4. The Future of Biosimilar Gene Therapies: Key Issues and Potential
5. IRA Reimbursement Impact on Biosimilars Minimal Despite Rising Market Share
6. The Role of Coverage...
2. Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
3. Formycon Reports €26.9 Million Revenue for First Half 2024, Driven by Biosimilars
4. CMS Announces New Drug Prices Under the IRA, Including for Stelara and Enbrel
5. FDA Approves Biosimilar Enzeevu for Eye Conditions
...
2. Ahzantive Receives FDA Approval as New Eylea Biosimilar
3. FDA Approves Epysqli as Second Soliris Biosimilar
4. BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
5. Biosimilars and Employers: Strategies for Success
6. Learning the Lingo of Biologics and Biosimilars Is Critical
7. Singapor...
To learn more about the Inflation Reduction Act's impact on biosimilars, click here.
2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology
3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
5. ASCO Posters Reflect on Reimbursement Trends,...
To watch Curtis and Edgerton speak on the approval of denosumab-bddz and osteoporosis treatment, click here.
To learn more about the ROSALIA study (NCT05405725), click here.
Extra content: To read more about the Biosimilars Council position paper on how to improve biosimilar development, click here.
- FDA Approves High-Concentration Cyltezo
- Eye on Pharma: Simlandi US Launch; Ranibizumab Partnership; Expanded Access for Adalimumab Biosimilars
- DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use
- Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD
- New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching
- Spanish Real-World Study: Adalimumab Biosi...
To read the full report, click here.
To check out The Center for Biosimilars coverage of Festival of Biologics USA, click here.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
AON Saves Over $243 Million With High Biosimilar Adoption
Julie Reed: Why 2024 Is Important for Biosimilars
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainabi...
- AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
- Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics
- Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
- Adalimumab Expenditures in Countries With and Without Available Biosimilars
- Review: Real-World Evidence Confirms Effectiveness and Safety ...
To learn more about Congress' role in addressing AbbVie's alleged anticompetitive practices regarding adalimumab products, click here.
To learn more about the suit filed by CareFirst BlueCross BlueShield regarding ustekinumab biosimilar delays, click here.
To learn more about t...
Popular Podcasts
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Rewarded for bravery that goes above and beyond the call of duty, the Medal of Honor is the United States’ top military decoration. The stories we tell are about the heroes who have distinguished themselves by acts of heroism and courage that have saved lives. From Judith Resnik, the second woman in space, to Daniel Daly, one of only 19 people to have received the Medal of Honor twice, these are stories about those who have done the improbable and unexpected, who have sacrificed something in the name of something much bigger than themselves. Every Wednesday on Medal of Honor, uncover what their experiences tell us about the nature of sacrifice, why people put their lives in danger for others, and what happens after you’ve become a hero. Special thanks to series creator Dan McGinn, to the Congressional Medal of Honor Society and Adam Plumpton. Medal of Honor begins on May 28. Subscribe to Pushkin+ to hear ad-free episodes one week early. Find Pushkin+ on the Medal of Honor show page in Apple or at Pushkin.fm. Subscribe on Apple: apple.co/pushkin Subscribe on Pushkin: pushkin.fm/plus
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The World's Most Dangerous Morning Show, The Breakfast Club, With DJ Envy, Jess Hilarious, And Charlamagne Tha God!
The official podcast of comedian Joe Rogan.